HCA Healthcare Inc - Company Profile
Powered by 
All the data and insights you need on HCA Healthcare Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date HCA Healthcare Inc Strategy Report
- Understand HCA Healthcare Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Related keylists
HCA Healthcare Catalyst Calendar
Proactively evaluate HCA Healthcare Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of HCA Healthcare Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 09 Sep 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 01 Sep 2019 | Phase II Trial Initiation | Bristol-Myers Squibb Co; Sarah Cannon Research Institute LLC; WindMIL Therapeutics Inc | BMY | Cellular Immunotherapy for Oncology; nivolumab | Oncology | Lung Cancer; Metastatic Lung Cancer; Non-Small Cell Lung Cancer; Solid Tumor; Squamous Non-Small Cell Lung Cancer | Clinical Trial Registry |
| 01 Sep 2019 | Phase I Trial Initiation | Molecular Templates Inc; Sarah Cannon Research Institute LLC; Translational Research In Oncology | MTEM | MT-5111 | Oncology | Adenocarcinoma Of The Gastroesophageal Junction; Colon Cancer; Gastric Cancer; Gastroesophageal (GE) Junction Carcinomas; Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer); Lung Cancer; Metastatic Biliary Tract Cancer; Metastatic Breast Cancer; Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer; Non-Small Cell Lung Cancer; Solid Tumor; Uterine Cancer | Clinical Trial Registry |
| 01 Sep 2019 | Phase I/II Trial Initiation | Cyteir Therapeutics Inc; Sarah Cannon Research Institute LLC | CYT | CYT-0851 | Oncology | B-Cell Non-Hodgkin Lymphoma; Breast Cancer; Chronic Lymphocytic Leukemia (CLL); Colorectal Cancer; Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Head And Neck Cancer; Head And Neck Cancer Squamous Cell Carcinoma; Leiomyosarcoma; Mantle Cell Lymphoma; Metastatic Breast Cancer; Metastatic Pancreatic Cancer; Multiple Myeloma (Kahler Disease); Non-Hodgkin Lymphoma; Ovarian Cancer; Pancreatic Cancer; Recurrent Head And Neck Cancer Squamous Cell Carcinoma; Refractory Chronic Lymphocytic Leukemia (CLL); Relapsed Chronic Lymphocytic Leukemia (CLL); Relapsed Multiple Myeloma; Sarcomas; Small-Cell Lung Cancer; Soft Tissue Sarcoma; Solid Tumor; Triple-Negative Breast Cancer (TNBC) | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer